Cyclacel pharmaceuticals reports fourth-quarter results

Cyclacel pharmaceuticals reports fourth quarter and full year 2019 financial results.qtrly net loss per share – basic and diluted $0.17.cyclacel pharmaceuticals- as of dec 31, 2019, cash and cash equivalents totaled $11.9 million, compared to $17.5 million as of december 31, 2018.

CYCC Ratings Summary

CYCC Quant Ranking